Capecitabine and streptozocin ± cisplatin for gastroenteropancreatic neuroendocrine tumours: predictors of long-term survival in the NET01 trial

Capecitabine and streptozocin ± cisplatin for gastroenteropancreatic neuroendocrine tumours: predictors of long-term survival in the NET01 trial

Bibliographic Details
Main Authors:	Meyer, T, Qian, W, Valle, J, Talbot, D, Cunningham, D, Reed, N, Wall, L, Waters, J, Ross, P, Anthoney, A, Sumpter, K, Sarwar, N, Crosby, T, Begum, N, Young, G, Hardy, R, Corrie, P
Format:	Conference item
Published:	Oxford University Press 2016

Similar Items

Gastroenteropancreatic neuroendocrine tumours.
by: Modlin, I, et al.
Published: (2008)

Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs).
by: Ramage, J, et al.
Published: (2012)

An overview of practical issues in the diagnosis of gastroenteropancreatic neuroendocrine pathology.
by: Chetty, R
Published: (2008)

A rare case of hepatic flexure Gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC)
by: Jasmani, Asraf Haslam, et al.
Published: (2022)

The relationship of survivin expression with tumour grade in gastroenteropancreatic neuroendocrine tumour (GEPNET)-USM experience
by: Hazmi, Hilma
Published: (2018)

Calcium Sensing receptor expression is downregulated in gastroenteropancreatic neuroendocrine tumours via epigenetic mechanisms
by: English, KA, et al.
Published: (2024)

Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours
by: Medley, L, et al.
Published: (2011)

Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours.
by: Medley, L, et al.
Published: (2011)

Methylation of SSTR2 in gastroenteropancreatic tumours
by: Simoglou Karali, C, et al.
Published: (2015)

Capecitabine: have we got the dose right?
by: Midgley, R, et al.
Published: (2009)

Capecitabine/irinotecan combination regimens in colorectal cancer.
by: Kerr, D
Published: (2002)

Capecitabine: Have we got the dose right?
by: Midgley, R, et al.
Published: (2009)

Capecitabine: Have we got the dose right?
by: Midgley, R, et al.
Published: (2009)

Neuroendocrine effects of sumatriptan.
by: Herdman, JR, et al.
Published: (1994)

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
by: Kerr, R, et al.
Published: (2016)

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
by: Love, S, et al.
Published: (2016)

MRI of pancreatic neuroendocrine tumours.
by: Owen, N, et al.
Published: (2001)

Neuroendocrine immune responses to inflammation: the concept of the neuroendocrine immune loop.
by: Chikanza, I, et al.
Published: (1996)

Preclinical models of neuroendocrine neoplasia
by: Sedlack, AJH, et al.
Published: (2022)

Pharmacoeconomic analysis of Capecitabine in the adjuvant setting. Results from the X-ACT trial comparing capecitabine with 5-FU/LV in patients with Dukes' C colon cancer
by: Douillard, J, et al.
Published: (2004)

Update on neuroendocrine tumours
by: Grossman, AB
Published: (2012)

A Phase I dose-finding and safety study of AZD8931 with Oxaliplatin and Capecitabine chemotherapy in patients with Oesophago-gastric adenocarcinoma: the randomised expansion phase of the DEBIOC trial
by: Thomas, A, et al.
Published: (2018)

Understanding and improving the anticancer activity of cisplatin
by: He, Qing, 1973-
Published: (2009)

A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring - supporting patients in their homes.
by: Weaver, A, et al.
Published: (2014)

Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials.
by: Kerr, D
Published: (2002)

Capecitabine/irinotecan in coloreetal cancer: European early-phase data and planned trials
by: Kerr, D
Published: (2002)

Genetics of neuroendocrine and carcinoid tumours.
by: Leotlela, P, et al.
Published: (2003)

Intraductal pancreatic neuroendocrine tumor.
by: Chetty, R, et al.
Published: (2009)

Ductules in pancreatic neuroendocrine tumors.
by: Chetty, R, et al.
Published: (2004)

Brain opiates and neuroendocrine function.
by: Grossman, A
Published: (1983)

Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
by: Mukherjee, S, et al.
Published: (2013)

Capecitabine (X) and oxaliplatin (O) combination chemotherapy in patients (pts) with advanced gall bladder or biliary tract cancer: A phase II study
by: Evans, T, et al.
Published: (2006)

Chemoprotection against cisplatin nephrotoxicity :: A molecular approach with selenium compounds
by: , BALDEW, Glenn Soerindre, et al.
Published: (1990)

Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: A UK nationwide cohort study 2013–2015
by: Genus, TSE, et al.
Published: (2019)

Sustained-release implants for intraperitoneal cisplatin delivery
by: Mantzavinou, Aikaterini
Published: (2019)

Consequences of Cisplatin Binding on Nucleosome Structure and Dynamics
by: Todd, Ryan C., et al.
Published: (2015)

The responses of cellular proteins to cisplatin-damaged DNA
by: Zamble, Deborah B. (Deborah Beth), 1971-
Published: (2012)

Mechanism-based rational design of cisplatin analogues
by: Barnes, Katie R., 1978-
Published: (2008)

Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2)
by: Strauss, V, et al.
Published: (2019)

Neuroendocrine responses to intravenous L-tryptophan in obsessive compulsive disorder.
by: Fineberg, N, et al.
Published: (1994)